ACOG extends the pregnancy RSV shot window through March — what changed this week

The most useful infant-health development this week is not another birth-story headline. It is a practical change in how long pregnant people can get a maternal RSV shot before spring.

## What changed

The American College of Obstetricians and Gynecologists published 2026-27 respiratory-virus immunization recommendations for pregnancy and the postpartum period. The calendar change: a single dose of the bivalent RSV Prefusion F vaccine (Abrysvo; Pfizer) is now recommended between 1 September and 1 March — later than the previous 31 January cutoff.

ACOG's reason is epidemiological. Recent RSV seasons have run later into spring and have been more severe. Extending the window is meant to cover infants who will still be in their highest-risk months when the virus is circulating.

The same guidance still treats COVID-19, influenza, and RSV vaccines as strongly recommended in pregnancy, postpartum, and when planning pregnancy, and says the three can be given together.

## Background

RSV is still the leading reason young children are hospitalized in the United States. Infants under six months carry the highest risk. Two tools exist:

1. A one-time maternal RSV shot in late pregnancy (Abrysvo is the product approved for that use). There are no good data yet on repeating it in later pregnancies.
2. An infant monoclonal antibody at birth — nirsevimab (Beyfortus) or clesrovimab (Enflonsia) — if the parent was not vaccinated, or if the infant is otherwise eligible.

Evidence reviews cited with the ACOG advisory put maternal vaccination in a 51-70% range against infant RSV hospitalization, and nirsevimab in a 64-93% range in the first season. Those are two different ways to get antibodies into a baby who cannot yet mount a strong response.

## Competing viewpoints

Clinicians who support the longer window argue that a January cutoff left March-born babies uncovered just as late-season RSV kept filling wards.

Skeptics point at a messier safety and policy picture:

- An FDA advisory discussion around pediatric RSV vaccine trials (not the maternal shot, and not the infant antibodies) asked for more infant safety data after severe RSV cases appeared in a Moderna pediatric trial.
- Adult RSV vaccines used in older people have added Guillain-Barre syndrome warnings. That signal is in seniors, not in the pregnancy indication.
- Coverage at birth hospitals is still uneven. Even when a product is recommended, many newborns leave without an antibody dose because of stocking, timing, or insurance friction.

Those debates should not be flattened into "RSV shots are unsafe for babies." The products, age groups, and evidence are different. They should also not be flattened into "everyone is covered now." Access is the remaining bottleneck.

## What to do this week

Ask the prenatal clinic three questions before the next visit:

- Are we still inside the September-March maternal RSV window for this pregnancy, and do you stock Abrysvo?
- If the shot is missed, will the birth hospital offer nirsevimab or clesrovimab before discharge?
- Can flu, COVID-19, and RSV be scheduled the same day if that is what we want?

If you already had the maternal RSV shot this pregnancy, you do not get a second dose. If this is a later pregnancy, say so — repeat-pregnancy data are still thin, and the infant antibody may be the cleaner path.

## What to watch next

- Whether hospitals actually extend ordering through March, or keep January inventory habits.
- Fine print on who gets a second-season infant antibody.
- How late the 2026-27 RSV curve actually runs in your region.

This is not medical advice. Use it to ask better questions of the clinicians who know your pregnancy.